Book a Meeting

Non-Fucosylated Anti-Human B7-H4 (2H9) Therapeutic Antibody (CAT#: BioBet-1428ZP) Datasheet

Target
B7-H4
Isotype
IgG
Description
ADCC-Enhanced anti-B7-H4 (2H9) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.
Indication
Cancer
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced B7-H4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
VTCN1
Full Name
V-set domain containing T cell activation inhibitor 1
Background
This gene encodes a protein belonging to the B7 costimulatory protein family. Proteins in this family are present on the surface of antigen-presenting cells and interact with ligand bound to receptors on the surface of T cells. Studies have shown that high levels of the encoded protein has been correlated with tumor progression. A pseudogene of this gene is located on chromosome 20. Multiple transcript variants encoding different isoforms have been found for this gene.
Alternative Names
VTCN1; V-set domain containing T cell activation inhibitor 1; B7X; B7H4; B7S1; B7-H4; B7h. 5; VCTN1; PRO129
Gene ID
79679
Cellular Localization
Plasma membrane
Involvement in Disease
Diseases associated with VTCN1 include Lung Cancer and Ovarian Cancer.
Related Pathways
Its related pathways are Cell adhesion molecules (CAMs) and NF-kappaB Signaling.
Function
By inhibiting T cell activation, proliferation, cytokine production and the development of cytotoxicity, it negatively regulates the immune response mediated by T cells. When expressed on the surface of tumor macrophages, it plays an important role together with regulatory T cells (Treg) to inhibit tumor-associated antigen-specific T cell immunity. Participate in the promotion of epithelial cell transformation.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Immune System antibody
Post-translational modifications
N-glycosylated.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
2H9
Host
Humanized
Species Reactivity
Human
Description
The antibody are capable of immunospecifically binding to B7-H4 and using in the diagnosis and the treatment of cancer and other diseases.
Indication
Cancer

Cancer

Related Products

Non-Fucosylated Anti-Human B7-H4 (2D1) Therapeutic Antibody (CAT#: BioBet-1429ZP)
Non-Fucosylated Anti-Human B7-H4 (Ab-A (Derived from 20502)) Therapeutic Antibody (CAT#: BioBet-1704ZP)
Non-Fucosylated Anti-Human B7-H4 (2E11) Therapeutic Antibody (CAT#: BioBet-1430ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany